Share
Andrew Davis
Endologix LLC, a leading privately held medical device company dedicated to advancing innovative therapies for vascular disease, has appointed Andrew Davis as its new Chief Commercial Officer.
With more than 25 years of experience in the medical device industry, Andrew brings a proven track record of commercial excellence and strategic leadership. Most recently, he served as Chief Commercial Officer at Silk Road Medical, where he led the successful go-to-market strategy for a transformative therapy addressing carotid artery disease (TCAR). His expertise spans revenue growth, market development, and customer engagement - key capabilities that align with Endologix’s long-term vision.
Throughout his career, Andy has played a pivotal role in launching and scaling minimally invasive therapies that address critical gaps in cardiovascular care. Prior to his time at Silk Road Medical, he served as Vice President of Sales and Marketing at 3M’s Advanced Wound Therapy Group.
His 15-year tenure at Medtronic included multiple senior leadership roles across Cardiac and Vascular Therapies, covering areas such as TAVR, EVAR/TEVAR, Peripheral Vascular, and Spine/Biologics.
Andy holds a B.S. in Political Science from Florida State University.
In his new role at Endologix, Andy will lead global commercial operations, drive strategic market initiatives, and strengthen customer relationships. His appointment marks a significant step in advancing the company’s mission to deliver cutting-edge vascular solutions and expand its impact worldwide.
